Oramed Pharmaceuticals (ORMP) & Its Competitors Critical Comparison

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Oramed Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, dividends, earnings, valuation, risk, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of current ratings and price targets for Oramed Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals 0 0 1 0 3.00
Oramed Pharmaceuticals Competitors 9926 15343 45764 1601 2.54

As a group, “Biotechnology” companies have a potential upside of 113.09%. Given Oramed Pharmaceuticals’ peers higher probable upside, analysts clearly believe Oramed Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Oramed Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals N/A -6.97% -6.01%
Oramed Pharmaceuticals Competitors -12,516.26% -215.37% -31.41%

Dividends

Oramed Pharmaceuticals pays an annual dividend of $0.25 per share and has a dividend yield of 6.9%. Oramed Pharmaceuticals pays out 4.1% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.4% and pay out 39.2% of their earnings in the form of a dividend. Oramed Pharmaceuticals is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.

Risk & Volatility

Oramed Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals’ peers have a beta of -1.87, meaning that their average stock price is 287% less volatile than the S&P 500.

Valuation & Earnings

This table compares Oramed Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oramed Pharmaceuticals $2.00 million $64.05 million 0.59
Oramed Pharmaceuticals Competitors $718.90 million $8.79 million -18.09

Oramed Pharmaceuticals’ peers have higher revenue, but lower earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

12.7% of Oramed Pharmaceuticals shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Oramed Pharmaceuticals beats its peers on 11 of the 15 factors compared.

Oramed Pharmaceuticals Company Profile

(Get Free Report)

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.